Edmonds Duncan Registered Investment Advisors, LLC Acelrx Pharmaceuticals Inc Transaction History

Edmonds Duncan Registered Investment Advisors, LLC

  • $446 Million
  • Q3 2024

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Jul 20, 2022
SELL
$0.18 - $0.29 $7,380 - $11,890
-41,000 Closed
0 $0
Q4 2021

Jan 27, 2022
BUY
$0.49 - $1.02 $7,350 - $15,300
15,000 Added 57.69%
41,000 $21,000
Q3 2021

Oct 19, 2021
SELL
$0.93 - $1.51 $13,950 - $22,650
-15,000 Reduced 36.59%
26,000 $27,000
Q4 2020

Feb 19, 2021
BUY
$1.18 - $1.98 $5,900 - $9,900
5,000 Added 13.89%
41,000 $89,000
Q3 2020

Nov 04, 2020
BUY
$1.01 - $1.81 $10,100 - $18,100
10,000 Added 38.46%
36,000 $51,000
Q2 2020

Jul 31, 2020
BUY
$1.03 - $1.69 $26,780 - $43,940
26,000 New
26,000 $31,000

About ACELRX PHARMACEUTICALS INC

ACRX Quotes by TradingView
  • Ticker ACRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 7,366,600
  • Market Cap $8.32M
  • Description
  • AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA and DZUVEO, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company develops ZALVISO, a pre-programmed ...
More about ACRX
Track This Portfolio

Track Edmonds Duncan Registered Investment Advisors, LLC Portfolio

Follow Edmonds Duncan Registered Investment Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Edmonds Duncan Registered Investment Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Edmonds Duncan Registered Investment Advisors, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email